Zoetis Inc. (ZTS) Stock: Price, Forecast & Analyst Target
Zoetis Inc. (ZTS) — MoonshotScore 87/100 (Exceptional band), calculated Nov 18, 2026. Price $85.57 (+2.50%), as of the Nov 18, 2026 trading session; market cap $34.8B. Expected results Feb 11, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Zoetis Inc. · ZTS · NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Research dated 2026-09-12: Zoetis develops and sells animal medicines, vaccines, diagnostics and related technologies to veterinarians, livestock producers and retail channels across companion-animal and livestock markets. The case depends on whether pricing support can protect demand and market share without weakening the strong profitability and cash generation that distinguish the business.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Zoetis (ZTS)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and durable growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Growing; Momentum: Rising.
- EPS beat 0 of the last 4 reports
- expected results Feb 11, 2027
- Altman Z 4.79 · Piotroski F 6
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 86 | Exceptional | |
| 87 | Exceptional | |
| 87 | Exceptional | |
| 87 | Exceptional | |
| 87 | Exceptional | |
| 87 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $85.57 | |
| Change on the day | +2.50% | |
| 52-week range | $68.77–$132.49 | |
| Market capitalisation | $34.8B | — |
| Price / earnings (trailing) | 14.17 | |
| Shares traded on the day | 4.66M | |
| Beta (volatility vs the S&P 500) | 0.68 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Zoetis (ZTS): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Zoetis (ZTS), and what does it report?
Short answer · as of
Zoetis is an animal-health company, not a conventional human-drug manufacturer. Demand comes from disease prevention, parasite control, pain and allergy treatment, oncology, reproductive care, diagnostic testing and livestock productivity across dogs, cats, horses, cattle, swine, poultry, fish and sheep.
Research dated 2026-09-12.
Reported revenue therefore reflects a broad mix of veterinary pharmaceuticals, vaccines, diagnostics, laboratory services and related animal-health offerings sold directly and through distributors. Species categories help describe exposure, while the consolidated statements capture the economics of the portfolio as a whole.
What do the latest results show for Zoetis (ZTS)?
Research dated 2026-09-12.
Latest-period revenue edged above the comparable result, while operating profit and net income declined. Revenue also came in below the prevailing estimate, although reported earnings exceeded the estimate, leaving a mixed result: demand held roughly steady, but the profit conversion was weaker.
Management says it is accelerating gross-to-net pricing investments to maintain or increase volume and protect or gain share. That is the stated mechanism to watch, rather than an established explanation for the entire earnings movement: commercial concessions may support demand, but their value depends on whether volume and share respond without sustained margin erosion.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $2.42B | $721M | $1.63 (diluted) |
| Q4 FY2025 | $2.39B | $603M | $1.37 (diluted) |
| Q1 FY2026 | $2.26B | $601M | $1.42 (diluted) |
| Q2 FY2026 | $2.47B | $691M | $1.65 (diluted) |
What are the financial strengths and risks for Zoetis (ZTS)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Zoetis combines high gross and operating margins with recurring positive operating cash flow and continued capital investment. Annual revenue, net income and research spending have also advanced across the reported history, supporting the picture of a profitable franchise that continues to fund product development.
Leverage is the main financial constraint. Debt materially exceeds cash and short-term investments, and the company is in a net-debt position despite healthy liquidity ratios and limited net cash movement across the reported window. A prolonged trade-off between commercial pricing support and profitability would matter more under that capital structure than it would for a cash-rich peer.
What should you watch next at Zoetis (ZTS)?
Short answer · as of
The next earnings report is expected on Feb 11, 2027.
Research dated 2026-09-12.
Watch whether the next earnings release shows revenue returning above expectations while operating profit stabilizes relative to sales. That combination would indicate that commercial pricing support is helping defend demand without allowing concessions to consume the portfolio’s margin strength.
Cash conversion deserves equal attention: operating cash flow should continue to cover capital spending while liquidity remains resilient against the debt load. Research spending should also be tracked alongside annual growth, because Zoetis must replenish and extend a portfolio spanning therapeutics, vaccines and diagnostics rather than rely on a narrow product set.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Zoetis compare with its peers?
Short answer
Zoetis's score ranks 4th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Zoetis differs from a typical specialty-drug company because its customers treat animals rather than people, and its commercial reach spans veterinary clinics, livestock operations, distributors and retail channels. Pharmaceuticals and vaccines sit beside point-of-care instruments, reference laboratories, genetic testing, biodevices and precision-animal-health tools, creating several routes into the same care ecosystem.
The breadth cuts across companion animals and production animals, so demand is tied to pet care as well as herd and flock health. That diversification is genuinely distinctive, but it also makes species demand, channel conditions and commercial pricing actions more informative than a simple comparison with human pharmaceutical manufacturers.
| Company | Price | Market value | Score |
|---|---|---|---|
| $102.00 Nov 18, 2026 | $6.67B | 96 5-pillar Nov 18, 2026 | |
| $945.53 Nov 18, 2026 | $97.8B | 95 5-pillar Nov 18, 2026 | |
| $400.84 Nov 18, 2026 | $86.6B | 88 5-pillar Nov 18, 2026 | |
| Zoetis (ZTS) — this page | $85.57 | $34.8B | 87 |
| $348.28 Nov 18, 2026 | $66.5B | 86 5-pillar Nov 18, 2026 | |
| $285.38 Nov 18, 2026 | $75.2B | 78 5-pillar Nov 18, 2026 | |
| $14.98 Nov 18, 2026 | $12.5B | 77 5-pillar Nov 18, 2026 | |
| $9.08 Nov 18, 2026 | $39.8B | 75 5-pillar Nov 18, 2026 | |
| $28.96 Nov 18, 2026 | $6.02B | 74 5-pillar Nov 18, 2026 | |
| $21.27 Nov 18, 2026 | $68.0B | 73 5-pillar Nov 18, 2026 | |
| $13.99 Nov 18, 2026 | $2.43B | 70 5-pillar Nov 18, 2026 | |
| $21.88 Nov 18, 2026 | $7.62B | 66 5-pillar Nov 18, 2026 | |
| $42.23 Nov 18, 2026 | $49.3B | 57 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $74.00 – $95.00
- Consensus target
- $84.75
- Median target
- $84.00
Consensus record · Captured .
Measured against a quoted price of $85.57 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 30, 2026
- Transactions
- 26
- Identified insiders
- 13
- Purchases
- 0
- Sales
- 0
- Other transactions
- 26
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ZTS in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.14% | $33.26M | Added +254.9% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Zoetis (ZTS)?
Zoetis Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why is Zoetis not simply a human drug company for animals?
Zoetis sells more than medicines: its portfolio includes vaccines, point-of-care diagnostics, reference laboratory services, genetic testing, biodevices and precision-animal-health offerings. Revenue therefore depends on veterinary care and livestock health workflows, not merely prescriptions.
How could Zoetis pricing investments affect animal-health demand?
Management is using gross-to-net pricing investments to support volume and market share. The useful test is whether revenue and share respond while operating profit remains resilient, since concessions that preserve demand but erode profitability would weaken the economics.
Does Zoetis generate cash after funding its animal-health operations?
Operating cash flow has remained positive and above capital spending throughout the reported quarterly series. That supports internal funding capacity, although debt remains far above cash and short-term investments.
Why do companion animals and livestock matter differently to Zoetis?
Companion-animal demand runs through veterinary treatment, diagnostics and chronic-care products, while livestock demand includes disease prevention, anti-infectives, parasiticides, medicated feed additives and productivity tools. Exposure across these animal groups broadens the revenue base but leaves the portfolio sensitive to different care settings and purchasing channels.
What is the ZTS stock price today?
The last price recorded for Zoetis Inc. (ZTS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ZTS price target?
The analyst consensus price target for Zoetis Inc. (ZTS), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 19 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold ZTS
Funds in our ETF coverage that list ZTS among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Scharf ETF (KAT) | 3.91% |